Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Ordinary Shares, no par value
-
Shares outstanding
-
3.84B
-
Number of holders
-
5
-
Total 13F shares, excl. options
-
54.6K
-
Shares change
-
-314K
-
Total reported value, excl. options
-
$168K
-
Value change
-
-$705K
-
Number of buys
-
1
-
Number of sells
-
-3
-
Price
-
$3.07
Significant Holders of Can-Fite BioPharma Ltd. - Ordinary Shares, no par value (CANF) as of Q2 2023
8 filings reported holding CANF - Can-Fite BioPharma Ltd. - Ordinary Shares, no par value as of Q2 2023.
Can-Fite BioPharma Ltd. - Ordinary Shares, no par value (CANF) has 5 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.6K shares
of 3.84B outstanding shares and own 0% of the company stock.
Largest 9 shareholders include MORGAN STANLEY (33.3K shares), RHUMBLINE ADVISERS (17.1K shares), FIFTH THIRD BANCORP (3K shares), NATIONAL BANK OF CANADA /FI/ (600 shares), CITIGROUP INC (553 shares), Federation des caisses Desjardins du Quebec (53 shares), UBS Group AG (0 shares), ARMISTICE CAPITAL, LLC (0 shares), and TD Waterhouse Canada Inc. (20 shares).
This table shows the top 5 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.